Cited by 106Gastrointestinal motility and disordersDiabetes Treatment and ManagementDiabetes Management and Research

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM

Open access

Kong, M.-F., Stubbs, T. A., King, P., Macdonald, I. A., Lambourne, J. E., Blackshaw, P. E., Perkins, A. C., Tattersall, R. B.·1998·Diabetologia

DOI 10.1007/s001250050949

Open this paper in CoChat — free account Open PDF

Abstract

In a previous study we have shown that an intravenous infusion of pramlintide (an analogue of human amylin) delayed gastric emptying, but the dose of pramlintide was supraphysiological in relation to the amylin response to food in non-diabetic subjects. The purpose of this study was to examine the dose response relationship of subcutaneous injections of pramlintide on gastric emptying and to determine whether administration of the drug before one meal has an impact on the subsequent meal. Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design. None had autonomic neuropathy. Euglycaemia was maintained overnight before the study day. At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously. At 0 min they ate a standard meal consisting of a pancake, labelled with 99mTc, and a milkshake containing 3-ortho-methylglucose (3-OMG). Gastric emptying images were obtained for the next 8 h. At 240 min the subjects ate a similar meal, but on this occasion the pancake was labelled with (111)In. All three doses of pramlintide delayed emptying of the solid component of the first meal (p < 0.004) with no significant difference between the drug doses. There were no differences between placebo and pramlintide after the second meal. All three doses of pramlintide resulted in a prolongation in the time to peak plasma 3-OMG level (p < 0.0001) after the first meal but there was no difference after the second meal.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s001250050949

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
The Design and Analysis of Clinical Experiments
Fleiss, J. L. (1999) · Wiley eBooks · doi:10.1002/9781118032923 · Cited by 4,819
The Design and Analysis of Clinical Experiments.
Hills, M., & Fleiss, J. L. (1987) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2982050 · Cited by 3,261
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469
Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus
Horowitz, M., Harding, P. E., Maddox, A. F., Wishart, J. M., Akkermans, L. M. A., Chatterton, B. E., & Shearman, D. J. C. (1989) · Diabetologia · doi:10.1007/bf00265086 · Cited by 393
Hyperglycaemia slows gastric emptying in Type 1 (insulin-dependent) diabetes mellitus
Fraser, R., Horowitz, M., Maddox, A., Harding, P., Chatterton, B., & Dent, J. (1990) · Diabetologia · doi:10.1007/bf00400569 · Cited by 359
Effects of Meal Ingestion on Plasma Amylin Concentration in NIDDM and Nondiabetic Humans
Butler, P. C., Chou, J., Carter, W. B., Wang, Y.-N., Bu, B.-H., Chang, D., Chang, J.-K., & Rizza, R. A. (1990) · Diabetes · doi:10.2337/diab.39.6.752 · Cited by 330
The Effect of Acute Hyperglycemia on Gastric Emptying in Man
MacGregor, I. L., Gueller, R., Watts, H. D., & Meyer, J. H. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80008-x · Cited by 250
Gastric emptying in patients with insulin-requiring diabetes mellitus.
Keshavarzian, A., Fl, I., & Vaeth, J. (1987) · PubMed · Cited by 201
Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans
Hartter, E., Svoboda, T., Ludvik, B., Schuller, M., Lell, B., Kuenburg, E., Brunnbauer, M., Woloszczuk, W., & Prager, R. (1991) · Diabetologia · doi:10.1007/bf00404025 · Cited by 191

Show all 27 references

Sorted by citations

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Decreased Food Intake With Aging
Morley, J. E. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.suppl_2.81 · Cited by 430
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 470
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
Du, Y., Rayner, C. K., Jones, K. L., Talley, N. J., & Horowitz, M. (2018) · Diabetes Care · doi:10.2337/dc17-1536 · Cited by 182
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus
Ryan, G. J., Jobe, L. J., & Martin, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.009 · Cited by 161
Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps
Levetan, C. S., Want, L. L., Weyer, C., Strobel, S. A., Crean, J., Wang, Y., Maggs, D. G., Kolterman, O., Chandran, M., Mudaliar, S. R., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.1 · Cited by 157
Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition
Samsom, M., Szarka, L. A., Camilleri, M., Vella, A. V., Zinsmeister, A. R., & Rizza, R. A. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.6.g946 · Cited by 148
Diabetes medications and body weight
Mitri, J., & Hamdy, O. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903081725 · Cited by 134
Control of energy homeostasis by amylin
Lutz, T. A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0905-1 · Cited by 139
Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes
Kowalski, A. J. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0031 · Cited by 128
Weight Effect of Current and Experimental Drugs for Diabetes Mellitus
Purnell, J. Q., & Weyer, C. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302010-00004 · Cited by 113
Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112
Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes
Weyer, C., Gottlieb, A., Kim, D. D. H., Lutz, K., Schwartz, S. L., Gutiérrez, M. E. H., Wang, Y., Ruggles, J. A., Kolterman, O., & Maggs, D. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3074 · Cited by 108
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Ryan, G., Jobe, L., & Briscoe, T. (2008) · Drug Design, Development and Therapy · doi:10.2147/dddt.s3225 · Cited by 98
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 98
Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes
Pillay, K., & Govender, P. (2013) · BioMed Research International · doi:10.1155/2013/826706 · Cited by 101
Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats
Reidelberger, R. D., Arnelo, U., Granqvist, L., & Permert, J. (2001) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2001.280.3.r605 · Cited by 92
Food intake and ageing—the role of the gut
Parker, B. A., & Chapman, I. M. (2004) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.05.006 · Cited by 87
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87
Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187
Gedulin, B. R., Jodka, C. M., Herrmann, K., & Young, A. A. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.06.004 · Cited by 81
Gastric emptying in diabetes mellitus: relationship to blood-glucose control
Kong, M.-F., & Horowitz, M. (1999) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30062-4 · Cited by 80
Self-citation
Clinical Implications of Amylin and Amylin Deficiency
Kruger, D. F., Gatcomb, P., & Owen, S. K. (1999) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572179902500310 · Cited by 79
Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes
Davis, Daly, Walsh, Ilett, Beilby, Dusci, L. J., & Barrett, P. H. R. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00162.x · Cited by 75
Inhibition of Gastric Emptying
Young, A. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52006-4 · Cited by 79
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 75
Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes
Ceriello, A., Piconi, L., Quagliaro, L., Wang, Y., Schnabel, C. A., Ruggles, J. A., Gloster, M., Maggs, D. G., & Weyer, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.632 · Cited by 75
Unresolved Challenges with Insulin Therapy in Type 1 and Type 2 Diabetes: Potential Benefit of Replacing Amylin, a Second β -Cell Hormone
Edelman, S. V., & Weyer, C. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007390 · Cited by 76
Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis
Cepeda, M. S., Berlin, J. A., Gao, C. Y., Wiegand, F., & Wada, D. R. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01340.x · Cited by 71
Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy
Buse, J. B., Weyer, C., & Maggs, D. G. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.3.137 · Cited by 71
Effects of duodenal fat, protein or mixed‐nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans
Feinle, C., CHRISTEN, M., GRUNDY, D., Faas, H., Meier, O. C., Otto, B., & Fried, M. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00318.x · Cited by 70
Pramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus
Kruger, D. F., & Gloster, M. (2004) · Drugs · doi:10.2165/00003495-200464130-00003 · Cited by 70
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
Pullman, J. R., Darsow, T., & Frías, J. P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.203 · Cited by 65
Amylin-mediated control of glycemia, energy balance, and cognition
Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 66
Impaired Hyperglycemia-Induced Delay in Gastric Emptying in Patients With Type 1 Diabetes Deficient for Islet Amyloid Polypeptide
Woerle, H. J., Albrecht, M., Linke, R., Zschau, S., Neumann, C., Nicolaus, M., Gerich, J. E., Göke, B., & Schirra, J. J. (2008) · Diabetes Care · doi:10.2337/dc07-2446 · Cited by 59
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 60
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 57
Measurement of gastric emptying in diabetes
Phillips, L. K., Rayner, C. K., Jones, K. L., & Horowitz, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.06.005 · Cited by 53
IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants
Denroche, H. C., & Verchere, C. B. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0138 · Cited by 53
Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide
Mack, C. M., Smith, P. A., Athanacio, J., Xu, K., Wilson, J., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 51
Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 49
Diabetes mellitus and gastric emptying: questions and issues in clinical practice
Samsom, M., Bharucha, A. E., Gerich, J. E., Herrmann, K., Limmer, J., Linke, R., Maggs, D. G., Schirra, J. R. J., Vella, A. V., Wörle, H., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.974 · Cited by 49
Diabetic Gastroparesis and Glycaemic Control
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1281-8 · Cited by 46
Novel Pharmacologic Agents for Type 2 Diabetes
Uwaifo, G. I., & Ratner, R. E. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.006 · Cited by 45
Living with the enemy: from protein-misfolding pathologies we know, to those we want to know
Emwas, A.-H. M., Alghrably, M., Dhahri, M., Sharfalddin, A. A., Alsiary, R., Jaremko, M., Faa, G., Campagna, M., Congiu, T., Piras, M., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101391 · Cited by 43
Pramlintide acetate
McQueen, J. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050341 · Cited by 44
Euglycaemic hyperinsulinaemia does not affect gastric emptying in Type I and Type II diabetes mellitus
Kong, M., King, P., Macdonald, I. A., Blackshaw, P. E., Horowitz, M., Perkins, A. C., Armstrong, E., Buchanan, K. D., & Tattersall, R. B. (1999) · Diabetologia · doi:10.1007/s001250051164 · Cited by 40
Self-citation
The Role of Prandial Pramlintide in the Treatment of Adolescents With Type 1 Diabetes
Rodríguez, L. M., Mason, K. J., Haymond, M. W., & Heptulla, R. A. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e318159af8c · Cited by 38
Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight
Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38
Human Amylin: From Pathology to Physiology and Pharmacology
Ling, W., Huang, Y., Qiao, Y.-C., Zhang, X., & Zhao, H. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190328111833 · Cited by 37
Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract
Portincasa, P., Bonfrate, L., Wang, D. Q. ‐., Frühbeck, G., Garruti, G., & Ciaula, A. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13846 · Cited by 39
Carbohydrate and Satiety
Feinle, C., O’Donovan, D., & Horowitz, M. (2002) · Nutrition Reviews · doi:10.1301/002966402320243241 · Cited by 36
Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function
Hinshaw, L., Schiavon, M., Mallad, A., Man, C. D., Basu, R., Bharucha, A. E., Cobelli, C., Carter, R. E., Basu, A., & Kudva, Y. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00199.2014 · Cited by 38
Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes
Maggs, D. G., Macdonald, I. A., & Nauck, M. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00737.x · Cited by 34
Self-citation
Diabetes mellitus and the stomach
Stacher, G. (2001) · Diabetologia · doi:10.1007/s001250100619 · Cited by 29
Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes
Obasse, I., Taylor, M., Fullwood, N. J., & Allsop, D. (2017) · Interface Focus · doi:10.1098/rsfs.2016.0127 · Cited by 26
The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin‐induced hypoglycaemia in patients with type 1 diabetes
Amiel, S. A., Heller, S. R., Macdonald, I. A., Schwartz, S. L., Klaff, L. J., Ruggles, J. A., Weyer, C., Kolterman, O., & Maggs, D. G. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00417.x · Cited by 25
Self-citation
A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes
Kishiyama, C. M., Burdick, P., Cobry, E. C., Gage, V., Messer, L. H., McFann, K., & Chase, H. P. (2009) · PEDIATRICS · doi:10.1542/peds.2008-3750 · Cited by 21
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1261 · Cited by 21
In Silico Design of Optimal Ratio for Co-Administration of Pramlintide and Insulin in Type 1 Diabetes
Micheletto, F., Man, C. D., Kolterman, O., Chiquette, E., Herrmann, K., Schirra, J., Kovatchev, B., & Cobelli, C. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0054 · Cited by 24
Treating the elderly diabetic patient: special considerations
Barski, L., Kezerle, L., & Shalev, L. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48898 · Cited by 22
Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus
Hassan, K., & Heptulla, R. A. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00490.x · Cited by 21
Adjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
Amylin analogue as an antidiabetic agent
Day, C. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050030701 · Cited by 18
Diabetes Distress and Its Association with Clinical Outcomes in Patients with Type 2 Diabetes Treated with Pramlintide as an Adjunct to Insulin Therapy
Peyrot, M. F., Rubin, R. R., & Polonsky, W. H. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0031 · Cited by 18
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 17
Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times Relative to Subcutaneous Injection of Pramlintide in Subjects With Type 2 Diabetes
Kellmeyer, T., Kesty, N. C., Wang, Y., Frías, J. P., & Fineman, M. S. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007300949 · Cited by 16
Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy
Rubin, R. R., & Peyrot, M. F. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210804 · Cited by 16
Effects of a Patient Education Support Program on Pramlintide Adherence
Lorenzi, G. M., LaRue, S. M., & Collins, S. E. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.1.17 · Cited by 15
Weight Management in Type 2 Diabetes Mellitus
Siram, A. T., Yanagisawa, R. T., & Skamagas, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20208 · Cited by 15
Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes
Fang, J., Landersdorfer, C. B., Cirincione, B. B., & Jusko, W. J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9409-7 · Cited by 14
The latest pharmacotherapy options for type 1 diabetes
Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13
New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus
Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13
Neutron-activated 153Sm-ion-exchange resin as a tracer for gastrointestinal scintigraphy
Yeong, C. H., Abdullah, B. J. J., Ng, K.-H., Chung, L. Y., Goh, K., Sarji, S. A., & Perkins, A. C. (2011) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32834b3ac8 · Cited by 12
Self-citation
A Model of Glucose-Insulin-Pramlintide Pharmacokinetics and Pharmacodynamics in Type I Diabetes
Ramkissoon, C. M., Aufderheide, B., Bequette, B. W., & Palerm, C. C. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813517323 · Cited by 12
Amylin
Phillips, L. K., & Horowitz, M. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000216969.59375.39 · Cited by 12
Role of amylin in feeding and satiation
Lutz, T. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110587 · Cited by 11
A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data
Furió-Novejarque, C., Sala-Mira, I., Díez, J.-L., & Bondía, J. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107968 · Cited by 7
Comparison of the Post-Meal Glucose Response to Different Insulin Bolus Waveforms in Insulin Pump- and Pre-Meal Pramlintide-Treated Type 1 Diabetes Patients
King, A. B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0096 · Cited by 7
The Physiology of Amylin and Insulin
Martin, C. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706288s237 · Cited by 6
Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.1.9 · Cited by 6
Through the Looking Glass
Kruger, D. F., Aronoff, S. L., & Edelman, S. V. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707299766 · Cited by 6
Controlling Release by Gastroretention
Coffin, M. D., & Burke, M. D. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1004-1_17 · Cited by 6
Relation between serum amylin level and epilepsy
Benlier, N., Özer, G., & Orhan, N. (2020) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-020-00164-5 · Cited by 4
A Review of Pramlintide in the Management of Diabetes
Messer, C., & Green, D. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2369 · Cited by 2
New treatments of diabetes: The β-amylin agonists
Lebovitz, H. E. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.02.015 · Cited by 2
Considering Pramlintide Therapy for Postprandial Blood Glucose Control
Childs, B. P., Kesty, N. C., KLEIN, E. J., Rubin, R. R., & Wick, A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.2.108 · Cited by 2
Gastrointestinal Symptoms in Diabetes Occur Long before Diabetic Complications
Jung, H., Rhee, E., Lee, M.-Y., Park, J., Park, D. I., Jeon, W. K., & Sohn, C. I. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.4.210 · Cited by 1
Cytotoxic Mechanisms of Islet Amyloid Polypeptide in the Pathogenesis of Type-2 Diabetes Mellitus (T2DM)
Degaki, T. L., Lopes, D. H. J., & Sogayar, M. C. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_7 · Cited by 1
A review on the use of adjunctive therapies in artificial pancreas systems
Furió-Novejarque, C., Díez, J.-L., & Bondía, J. (2024) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2024.11.053 · Cited by 1
Combination Therapy for Treatment of Type 2 Diabetes
McCall, A. L. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-16 · Cited by 1
Appetite, food intake and ageing: The role of the gut
Parker, B. A. (2005) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 1
Of Mice and Men: Translational Research on Amylin Agonism
Roth, J. D., Mack, C. M., Trevaskis, J. L., & Parkes, D. G. (2011) · Wiley eBooks · doi:10.1002/9783527636730.ch14
Pharmacotherapy Of Type 2 Diabetes – The Future
Abhay, A. P., Ravichand, D. M., V.Seshayamma, & Chandran, P. (2006) · Intern J Endocrinol Metab
Characterization of Cardiovascular Outcomes in a Type 2 Diabetes Glucose Supply and Insulin Demand Model
Monte, S. V., Schentag, J. J., Adelman, M. H., & Paladino, J. A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400220
Pramlintide Acetate in the Treatment of Type 2 Diabetes
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-14 · Cited by 2

Authors: Kong, M.-F., Stubbs, T. A., King, P., Macdonald, I. A., Lambourne, J. E., Blackshaw, P. E., Perkins, A. C., & Tattersall, R. B.
Affiliations: Queen's Medical Centre (GB)
University of Nottingham (GB)
Nottingham University Hospitals NHS Trust (GB)
ORCID: Macdonald, I. A.
Perkins, A. C.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 1998-04-21
Volume: 41
Issue: 5
Pages: 577-583
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s001250050949
OpenAlex: W2041827953
Cited by: 106
References: 27
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 4 · 2013: 3 · 2012: 2
FWCI: 2.82
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Funders: Amylin Pharmaceuticals
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: pramlintide, amylin analogues, gastric emptying, type 1 diabetes, dose-response relationship, subcutaneous injection, plasma glucose response, autonomic neuropathy
MeSH terms: Adult, Amyloid, Blood Glucose, Energy Intake, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Food, Gastric Emptying, Humans, Hypoglycemic Agents, Insulin, Male, Cross-Over Studies, 3-O-Methylglucose, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks